As I've said more than once, the shares of biotech Achillion Pharmaceuticals (ACHN)
come with invisible mandatory tickets to a roller-coaster ride. This
biotech may have a compelling all-oral Hep C regimen in its pipeline,
but investors remain nervous that the company is going to be a distant
runner-up to the more advanced programs at Gilead (GILD) and AbbVie (ABBV).
With the shares down again on what I would consider "non-core"
concerns, aggressive investors may want to run the numbers on this
company and its stock.
Please continue here:
Aches And Pains Shouldn't Obscure Achillion's Potential
No comments:
Post a Comment